Biochemotherapy for advanced melanoma
- 1 October 2002
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (5) , 456-461
- https://doi.org/10.1053/sonc.2002.35240
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.Journal of Clinical Oncology, 1998
- Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trialsCancer, 1993
- Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experienceCancer, 1993
- Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanomaBritish Journal of Haematology, 1991
- Phase II Study of Intravenous Bolus Recombinant Interleukin-2 in Advanced Malignant Melanoma: Southwest Oncology Group StudyJNCI Journal of the National Cancer Institute, 1991
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: A phase I/II studyCancer Treatment Reviews, 1989
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985